Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Solo, offers from our innovative technical platforms
Home . Service . SOLO: offers from our innovative technical platforms
A wide range of distinct and diversified services
An extension of our innovation technology platforms, SOLO involves a wide range of distinct and diversified services. It covers an extensive spectrum of pharmaceutical expertise and the ability to design and carry out precise and ad hoc assessments in the discovery and development of new therapies. Drawing on our experience and expertise in the preclinical investigation of new therapeutic entities – with different mechanisms of action – in various indications, and given our mastery of cutting-edge translational technologies, our SOLO services are a guarantee of quality and excellence to meet various needs and specificities.
SOLO is also the answer for the development of new, relevant and more predictive disease models that are needed to better characterize and qualify exploratory and innovative therapeutic approaches. These developments can be carried out in partnership with our customers.